Evaluating Source Data Verification as a Quality Control Measure in Clinical Trials

被引:31
作者
Sheetz, Nicole [1 ]
Wilson, Brett [2 ]
Benedict, Joanne [3 ]
Huffman, Esther [2 ]
Lawton, Andy [4 ]
Travers, Mark [5 ]
Nadolny, Patrick [6 ]
Young, Stephen [7 ]
Given, Kyle [8 ]
Florin, Lawrence [9 ]
机构
[1] Eli Lilly & Co, Clin Dev Innovat, Indianapolis, IN 46285 USA
[2] Bristol Myers Squibb Co, Global Dev Operat, Princeton, NJ 08540 USA
[3] Genentech Inc, Roche, Global Prod Dev, San Francisco, CA 94080 USA
[4] Boehringer Ingelheim GmbH & Co KG, Biometr & Data Management, Bracknell, Berks, England
[5] Sanofi, Clin Sci & Operat, Bridgewater, NJ USA
[6] Allergan Pharmaceut Inc, Bioinformat Operat & Syst, Irvine, CA USA
[7] Medidata Solut, Strateg Consulting Serv, Conshohocken, PA USA
[8] Medidata Solut, Strateg Consulting Serv, Edison, NJ USA
[9] Medidata Solut, Consulting Partnerships, Conshohocken, PA USA
关键词
source data verification; source data review; risk-based monitoring; quality control; data integrity; SOURCE DOCUMENT VERIFICATION;
D O I
10.1177/2168479014554400
中图分类号
R-058 [];
学科分类号
摘要
TransCelerate has developed a risk-based monitoring methodology that transforms clinical trial monitoring from a model rooted in source data verification (SDV) to a comprehensive approach leveraging cross-functional risk assessment, technology, and adaptive on-site, off-site, and central monitoring activities to ensure data quality and subject safety. Evidence suggests that monitoring methods that concentrate on what is critical for a study and a site may produce better outcomes than do conventional SDV-driven models. This article assesses the value of SDV in clinical trial monitoring via a literature review, a retrospective analysis of data from clinical trials, and an assessment of major and critical findings from TransCelerate member company internal audits. The results support the hypothesis that generalized SDV has limited value as a quality control measure and reinforce the value of other risk-based monitoring activities.
引用
收藏
页码:671 / 680
页数:10
相关论文
共 21 条
[1]   Accuracy of data transfer: double data entry and estimating levels of error [J].
Atkinson, Ian .
JOURNAL OF CLINICAL NURSING, 2012, 21 (19-20) :2730-2735
[2]   Ensuring trial validity by data quality assurance and diversification of monitoring methods [J].
Baigent, Colin ;
Harrell, Frank E. ;
Buyse, Marc ;
Emberson, Jonathan R. ;
Altman, Douglas G. .
CLINICAL TRIALS, 2008, 5 (01) :49-55
[3]   The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial [J].
Bakobaki, Julie M. ;
Rauchenberger, Mary ;
Joffe, Nicola ;
McCormack, Sheena ;
Stenning, Sally ;
Meredith, Sarah .
CLINICAL TRIALS, 2012, 9 (02) :257-264
[4]   Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials [J].
Brosteanu, Oana ;
Houben, Peggy ;
Ihrig, Kristina ;
Ohmann, Christian ;
Paulus, Ursula ;
Pfistner, Beate ;
Schwarz, Gabriele ;
Strenge-Hesse, Anke ;
Zettelmeyer, Ulrike .
CLINICAL TRIALS, 2009, 6 (06) :585-596
[5]   Post-analytical errors with portable glucose meters in the hospital setting [J].
Carraro, Paolo ;
Plebani, Mario .
CLINICA CHIMICA ACTA, 2009, 404 (01) :65-67
[6]  
De Sourabh, 2011, Perspect Clin Res, V2, P100, DOI 10.4103/2229-3485.83226
[7]   Specific barriers to the conduct of randomized trials [J].
Duley, Lelia ;
Antman, Karen ;
Arena, Joseph ;
Avezum, Alvaro ;
Blumenthal, Mel ;
Bosch, Jackie ;
Chrolavicius, Sue ;
Li, Timoa ;
Ounpuu, Stephanie ;
Perez, Analia Cristina ;
Sleight, Peter ;
Svard, Robbyno ;
Temple, Robert ;
Tsouderous, Yannis ;
Yunis, Carla ;
Yusuf, Salim .
CLINICAL TRIALS, 2008, 5 (01) :40-48
[8]  
European Medicines Agency Science Medicinces Health, 2013, EMA2690112013
[9]  
Funning S., 2009, QUAL ASSUR J, V12, P3, DOI [DOI 10.1002/QAJ.433, 10.1002/qaj.433]
[10]  
Grahnen A, 2007, CLIN PHARMACOL THER, V81, pS21